Financing ·
Vivos Therapeutics, Inc. entered into a letter agreement with Streeterville Capital, LLC on June 18, 2026, to amend an…
VVOSVivos Therapeutics, Inc.
Vivos Therapeutics, Inc. entered into a letter agreement with Streeterville Capital, LLC on June 18, 2026, to amend an existing Exchange Agreement. The amendment extends the deadline for the Company to complete a qualifying financing of at least $2,600,000 by which date must be completed by August 31, 2026. Vivos Therapeutics, Inc. operates in the biotechnology industry and develops medical technology for monitoring and managing health data.